Wittycell, Pépinière Genopole Entreprises, Campus 3-4, rue Pierre Fontaine, 91058 EVRY Cedex, France.
Expert Rev Vaccines. 2011 Aug;10(8):1207-20. doi: 10.1586/erv.11.84.
Despite the library of new adjuvants available for use in vaccines, we remain, at present, almost reliant on aluminum-based compounds for clinical use. The increasing use of recombinant subunit vaccines, however, makes the need for improved adjuvant of particular interest. Adjuvants are crucial components of all cancer vaccines whether they are composed of whole cells, proteins or peptides. For the purposes of this article, cellular adjuvant products are defined as adjuvants associated with cellular or T-cell immunity. Several pharmaceutical companies are developing new adjuvants or immune enhancers for the treatment of cancers such as melanoma and non-small-cell lung carcinoma. Several products are being developed and have entered clinical trials either alone or in combination. In this article, we discuss recent adjuvant development and novel cellular adjuvant products for therapeutic cancer vaccines.
尽管有许多新的佐剂可用于疫苗，但目前我们几乎仍然依赖于铝基化合物用于临床应用。然而，随着重组亚单位疫苗的日益使用，对改良佐剂的需求变得尤为重要。佐剂是所有癌症疫苗的关键组成部分，无论它们是由全细胞、蛋白质还是肽组成。就本文而言，细胞佐剂产品被定义为与细胞或 T 细胞免疫相关的佐剂。几家制药公司正在开发新的佐剂或免疫增强剂来治疗黑色素瘤和非小细胞肺癌等癌症。一些产品正在开发中，并已单独或联合进入临床试验。本文讨论了最近佐剂的发展和新型细胞佐剂产品用于治疗性癌症疫苗。
